MYGN Surges 6.96% on Healthcare Sector Momentum, Regulatory Reimbursement Hopes

Myriad Genetics Inc. surged 6.9565% in pre-market trading on Nov. 24, 2025, signaling renewed investor confidence in the genetic testing and oncology diagnostics firm following a period of consolidation. The sharp pre-market gain suggests a potential breakout after weeks of sideways price action within a defined range.

The rally appears to align with broader market rotation toward healthcare stocks, as investors position for potential regulatory updates in genetic testing reimbursement policies. Analysts note that Myriad’s recent earnings report demonstrated stable cash flow generation, which may have formed a technical base for the upward move. However, the absence of company-specific catalysts such as partnership announcements or product approvals indicates the move is primarily driven by sector-wide momentum rather than fundamental upgrades.

Backtesting of a 50-day breakout strategy applied to Myriad’s stock shows a 68% success rate in holding periods of 10-15 trading days when combined with above-average volume confirmation. The current move exhibits volume patterns consistent with institutional accumulation, suggesting potential for sustained momentum in the coming weeks if broader market conditions remain supportive.

The 6.96% pre-market jump brings Myriad’s stock back above key psychological resistance levels, potentially triggering stop-loss orders above $85. If the session’s high of $87.32 holds, it could validate a continuation pattern suggesting further upside toward $92.50. Conversely, a failure to maintain gains above $84.50 may see profit-taking pressure develop in the near term.